FIELD: medicine.
SUBSTANCE: invention refers to biotechnology. What is described is a method for predicting an individual's response to a therapeutic agent for treating rheumatoid arthritis (RA). What is also presented is a method for predicting if the individual suffering RA responds to the B-cell antagonist therapy. There are also presented method of predicting if the individual with rheumatoid arthritis responds to the B-cell antagonist therapy effectively and method for selecting the therapy of patients or patients' subpopulation with rheumatoid arthritis. All the methods involves measuring a biological sample prepared from the individual to determine an expression of one gene or a combination thereof or an expression of one protein or a combination thereof coded by one gene or a combination thereof, wherein one gene or a combination thereof are specified in any of CXCL13, FcRH5 and sFcRH5.
EFFECT: invention extends the diagnostic capabilities in relation to RA.
20 cl, 14 dwg, 13 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| DETERGENT COMPOSITION | 2010 |
|
RU2546834C2 |
| ENRICHED NUTRIENT MEDIUM FOR GROWING CELLS DERIVED FROM HUMAN UMBILICAL CORD TISSUE | 2013 |
|
RU2653449C2 |
| ENRICHED NUTRIENT MEDIUM FOR GROWING CELLS DERIVED FROM HUMAN UMBILICAL CORD TISSUE | 2013 |
|
RU2684306C2 |
| BIOLOGICAL MARKERS FOR IDENTIFYING PATIENTS FOR TREATMENT WITH VEGF ANTAGONISTS | 2013 |
|
RU2659173C2 |
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
| HYBRID PROTEIN-BASED POLYVALENT INFLUENZA VACCINE | 2013 |
|
RU2531235C2 |
| ANTIBODY DRUG CONJUGATES | 2014 |
|
RU2669812C2 |
| RECOMBINANT PORCINE CIRCOVIRUSES 2 (PCV-2) ANTIGENS FOR VACCINE COMPOSITIONS, DIAGNOSTIC KIT AND USE THEREOF | 2014 |
|
RU2687001C2 |
| SPLICEOSTATIN ANALOGS | 2013 |
|
RU2618523C2 |
| SPECIFIC PLADIENOLIDE COMPOUNDS AND METHODS OF THEIR USE | 2019 |
|
RU2813597C2 |
